Literature DB >> 18594118

A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma.

Claes Bergmark1, Asheesh Dewan, Alexina Orsoni, Esther Merki, Elizabeth R Miller, Min-Jeong Shin, Christoph J Binder, Sohvi Hörkkö, Ronald M Krauss, M John Chapman, Joseph L Witztum, Sotirios Tsimikas.   

Abstract

Oxidized phospholipids (OxPLs) on apolipoprotein B-100 (apoB-100) particles are strongly associated with lipoprotein [a] (Lp[a]). In this study, we evaluated whether Lp[a] is preferentially the carrier of OxPL in human plasma. The content of OxPL on apoB-100 particles was measured with monoclonal antibody E06, which recognizes the phosphocholine (PC) headgroup of oxidized but not native phospholipids. To assess whether OxPLs were preferentially bound by Lp[a] as opposed to other lipoproteins, immunoprecipitation and ultracentrifugation experiments, in vitro transfer studies, and chemiluminescent ELISAs were performed. Immunoprecipitation of Lp[a] from human plasma with an apolipoprotein [a] (apo[a])-specific antibody demonstrated that more than 85% of E06 reactivity (i.e., OxPL) coimmunoprecipitated with Lp[a]. Ultracentrifugation experiments showed that nearly all OxPLs were found in fractions containing apo[a], as opposed to other apolipoproteins. In vitro transfer studies showed that oxidized LDL preferentially donates OxPLs to Lp[a], as opposed to LDL, in a time- and temperature-dependent manner, even in aqueous buffer. Approximately 50% of E06 immunoreactivity could be extracted from isolated Lp[a] following exposure of plasma to various lipid solvents. These data demonstrate that Lp[a] is the preferential carrier of PC-containing OxPL in human plasma. This unique property of Lp[a] suggests novel insights into its physiological function and mechanisms of atherogenicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18594118     DOI: 10.1194/jlr.M800174-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  108 in total

1.  Modification of lipoprotein(a) by natural dicarbonyls induced their following free radical peroxidation.

Authors:  V Z Lankin; O I Afanasieva; G G Konovalova; E A Utkina; O A Dmitrieva; A K Tikhaze; E M Kumskova; S N Pokrovsky
Journal:  Dokl Biochem Biophys       Date:  2012-01-06       Impact factor: 0.788

2.  Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet.

Authors:  Nastaran Faghihnia; Sotirios Tsimikas; Elizabeth R Miller; Joseph L Witztum; Ronald M Krauss
Journal:  J Lipid Res       Date:  2010-08-16       Impact factor: 5.922

Review 3.  Genetics of lipid traits and relationship to coronary artery disease.

Authors:  Tanya E Keenan; Daniel J Rader
Journal:  Curr Cardiol Rep       Date:  2013-09       Impact factor: 2.931

4.  Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a).

Authors:  Corey A Scipione; Sera E Sayegh; Rocco Romagnuolo; Sotirios Tsimikas; Santica M Marcovina; Michael B Boffa; Marlys L Koschinsky
Journal:  J Lipid Res       Date:  2015-10-16       Impact factor: 5.922

Review 5.  Lipoprotein (a): Coming of Age at Last.

Authors:  Joseph L Witztum; Henry N Ginsberg
Journal:  J Lipid Res       Date:  2016-02-02       Impact factor: 5.922

Review 6.  Update on lipoprotein(a) as a cardiovascular risk factor and mediator.

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  Curr Atheroscler Rep       Date:  2013-10       Impact factor: 5.113

Review 7.  Oxidation-specific epitopes as targets for biotheranostic applications in humans: biomarkers, molecular imaging and therapeutics.

Authors:  Yury I Miller; Sotirios Tsimikas
Journal:  Curr Opin Lipidol       Date:  2013-10       Impact factor: 4.776

8.  Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial.

Authors:  Young Sup Byun; Jun-Hee Lee; Benoit J Arsenault; Xiaohong Yang; Weihang Bao; David DeMicco; Rachel Laskey; Joseph L Witztum; Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2015-04-07       Impact factor: 24.094

Review 9.  Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.

Authors:  Adam Taleb; Joseph L Witztum; Sotirios Tsimikas
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

10.  Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress.

Authors:  Tracie A Seimon; Marissa J Nadolski; Xianghai Liao; Jorge Magallon; Matthew Nguyen; Nicole T Feric; Marlys L Koschinsky; Richard Harkewicz; Joseph L Witztum; Sotirios Tsimikas; Douglas Golenbock; Kathryn J Moore; Ira Tabas
Journal:  Cell Metab       Date:  2010-11-03       Impact factor: 27.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.